CME/CE INFORMATION
Oncology Congress
Saturday, April 1, 2023 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT
HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:
- Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it. - Step 2: Complete Evaluation(s)
Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended. - Step 3: View and Print Certificate(s)
After you’ve completed the evaluation(s), click the blue Print Certificate button to view and print your CME/CE certificate(s).
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer:
Strategies for Improving Care and Outcomes
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by an independent medical education grant from GlaxoSmithKline.
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Identify key barriers in ovarian cancer care in rural and underserved settings
- Evaluate the safety and efficacy of PARP inhibitors as maintenance therapy for ovarian cancer
- Apply key findings from clinical trials and expert guidance to the selection of maintenance treatment for ovarian cancer
- Develop team-based strategies to improve the recognition and management of adverse events associated with PARP inhibitor use for ovarian cancer
FACULTY
Robert L. Coleman, MD
Chief Medical Officer
Sarah Cannon Research Institute
Gynecologic Oncologist
US Oncology - Texas Oncology
Houston, TX
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Robert L. Coleman, MD, has disclosed the following relevant financial relationships: consultant for AbbVie, Inc., Agenus, Inc., Alkermes, AstraZeneca Pharmaceuticals, Clovis Oncology, Deciphera Pharmaceuticals, Genelux Corporation, Genmab, GlaxoSmithKline, ImmunoGen, OncoQuest, Inc., OncXerna Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Roche/Genentech, Inc., Novocure, and Merck & Co., Inc.; grant/research support from AstraZeneca Pharmaceuticals, Clovis Oncology, Genelux Corporation, Genmab, Merck & Co., Inc., ImmunoGen, and Roche/Genentech, Inc.; speakers’ bureau/honoraria from AstraZeneca Pharmaceuticals, Clovis Oncology, Roche/Genentech, Inc., and Merck & Co., Inc.; advisory board/Data Safety Monitoring Board for Eisai, Inc./Bristol Myers Squibb and VBL Therapeutics.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
Navigating New Evidence in the Treatment of HER2-Expressing
Metastatic Breast Cancer in Rural and Underserved Communities
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Seagen.
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Explain the evolving role of HER2 testing in determining treatment selection in patients with HER2-expressing breast cancer
- Evaluate the efficacy and safety of current and emerging treatments for HER2-expressing metastatic breast cancer
- Integrate current guidelines and clinical evidence on sequencing of therapies into personalized treatment plans for patients with HER2-expressing metastatic breast cancer
- Identify evidence-based strategies for reducing disparities in breast cancer care access and treatment in rural and underserved settings
FACULTY
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma
to Ensure Equitable Access to Quality Care
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by independent medical education grants from Eisai, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Evaluate available therapies for metastatic renal cell carcinoma (RCC) based on their efficacy and safety profiles
- Apply the latest guidelines and clinical evidence into the development of treatment plans for patients with metastatic RCC in the first- and subsequent-line settings
- Implement evidence-based strategies for reducing disparities in RCC care in rural and underserved communities
FACULTY
Martin H. Voss, MD
Clinical Director
Genitourinary Oncology Service
Associate Member
Memorial Sloan Kettering Cancer Center
New York, NY
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Martin H. Voss, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Affimed, AVEO Oncology, Eisai, Inc., Exelixis, Inc., Genentech, Inc., Merck & Co., Inc., MicuRx Pharmaceuticals, Inc., and Oncorena; grant/research support from AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Merck & Co., Inc., Pfizer, Inc., and Roche/Genentech, Inc.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Integrating the Latest Evidence in Melanoma Care to Address Health Equity
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by independent medical education grants from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc.
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Implement strategies to reduce melanoma health disparities in rural and underserved populations
- Apply clinical evidence and recommendations for initial treatment selection and sequencing of therapy for patients with metastatic melanoma
- Develop a plan for preventing, monitoring, and mitigating adverse events associated with treatments for advanced and metastatic melanoma
FACULTY
Michael A. Davies, MD, PhD
Professor and Chair
Department of Melanoma Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Michael A. Davies, MD, PhD, has disclosed the following relevant financial relationships: consultant/advisory board member for ABM Therapeutics, Bristol Myers Squibb, Eisai, Inc., Genentech, Inc., Iovance, and Novartis Pharmaceuticals Corporation; grant/research support from ABM Therapeutics, Lead Pharma, and Pfizer, Inc.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Integrating the Latest Evidence on Management of Basal Cell Carcinoma:
Improving Outcomes in Rural and Underserved Communities
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Implement evidence-based strategies for reducing disparities in basal cell carcinoma care in rural and underserved settings
- Differentiate treatment options for basal cell carcinoma based on clinical efficacy and safety data
- Integrate clinical evidence and current guideline recommendations into treatment plans for patients with basal cell carcinoma
- Recognize adverse events associated with therapies for basal cell carcinoma to improve adherence to therapy
FACULTY
David M. Miller, MD, PhD
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Hospital
Boston, MA
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
David M. Miller, MD, PhD, has disclosed the following relevant financial relationships: advisory board member for Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Inc., Merck & Co., Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; research/grant support from Kartos Therapeutics, NeoImmuneTech, Inc., and Regeneron Pharmaceuticals, Inc.; ownership/stock options from Avstera Therapeutics and Checkpoint Therapeutics.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
Integrating Novel Treatment Approaches for Cutaneous Squamous Cell Carcinoma:
Strategies for Improving Equitable and Timely Access to Care
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
TARGET AUDIENCE
This
activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
LEARNING OBJECTIVES
- Summarize the clinical evidence for the efficacy and safety of new and emerging therapeutic options and treatment strategies for cutaneous squamous cell carcinoma
- Develop individualized management plans for advanced and metastatic cutaneous squamous cell carcinoma, incorporating current guideline recommendations, clinical data, and best practices
- Implement evidence-based strategies for reducing disparities in cutaneous squamous cell carcinoma care and treatment in rural and underserved settings
FACULTY
David M. Miller, MD, PhD
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Hospital
Boston, MA
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
David M. Miller, MD, PhD, has disclosed the following relevant financial relationships: advisory board member for Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Inc., Merck & Co., Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; research/grant support from Kartos Therapeutics, NeoImmuneTech, Inc., and Regeneron Pharmaceuticals, Inc.; ownership/stock options from Avstera Therapeutics and Checkpoint Therapeutics.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
- System checker: Must meet all requirements of Digitell Live Events Platform
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
FEE INFORMATION
There is no fee for this educational activity.
COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.